Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: A nested case-control study

AIDS

Volumn 24, Issue 4, 2010, Pages 525-534

  Judd, Ali ^a   Boyd, Katherine L ^a   Stöhr, Wolfgang ^a   Dunn, David ^a   Butler, Karina ^b   Lyall, Hermione ^c   Sharland, Mike ^d   Shingadia, Delane ^e   Riordan, Andrew ^f   Gibb, Di M ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Case control study; Ireland; Paediatrics; Renal abnormality; Tenofovir disoproxil fumarate; UK

Indexed keywords

ALBUMIN; CALCIUM; CREATININE; PHOSPHATE; POTASSIUM; SODIUM; TENOFOVIR DISOPROXIL; UREA;

ADOLESCENT; ANTIVIRAL THERAPY; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOPHOSPHATEMIA; KIDNEY CALCIFICATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROXIMAL RENAL TUBULAR DYSFUNCTION; RISK FACTOR; SCHOOL CHILD; TUBULAR DYSFUNCTION;

ADENINE; ADOLESCENT; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENGLAND; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV-1; HUMANS; HYPOPHOSPHATEMIA; IRELAND; KIDNEY; MALE; PHOSPHONIC ACIDS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 77649267512     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283333680     Document Type: Article

References (33)

1. Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006; 42:1488-1495.
2. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40: 1331-1333.
3. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-1073.
4. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndromes 2004; 35:269-273.
5. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42:283-290.
6. Kapitsinou PP, Ansari N. Acute renal failure in an AIDS patient on tenofovir: a case report. J Med Case Rep 2008; 2: 94.
7. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dialysis Transplant 2005; 20:743-746.
8. Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, Cheng AK, Enejosa JV. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in anti-retroviral-naive patients. AIDS 2008; 22:2155-2163.
9. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-1263.
10. Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Internal Med 2003; 139:313-320.
11. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198.
12. Reid A, Stohr W, Walker AS, Williams IG, Kityo C, Hughes P, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008; 46:1271-1281.
13. Young B, Buchacz K, Baker RK, Moorman AC, Wood KC, Chmiel J, Brooks JT, Hiv Outpatient Study I. Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Phys AIDS Care 2007; 6:178-187.
14. Buchacz K, Brooks JT, Tong T, Moorman AC, Baker RK, Holmberg SD, Greenberg A. Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med 2006; 7:451-456.
15. Reid A, Stohr W, Walker AS, Hakim J, Ssali F, Munderi P, et al. Glomerular dysfunction and associated risk factors through four years following initiation of ART in adults with HIV Infection in Africa in the DART trial. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town; 2009.
16. Madeddu G, Bonfanti P, De Socio GV, Carradori S, Grosso C, Marconi P, et al. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother 2007. doi:10.1016/j.biopha.2007.04.008.
17. Crane HM, Kestenbaum B, Harrington RD, Kitahata MM. Am-prenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 2007; 21:1431-1439.
18. Hussain S, Khayat A, Tolaymat A, Rathore MH. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatric Nephrol 2006; 21:1034-1036.
19. Hawkins S, Ball C. Adverse events experienced by three children taking tenofovir and didanosine in combination. HIV Med 2007; 8:411.
20. Onyeador N, Patel D, Lyall H, Tudor-Williams G, Walters S, Foster CJ. Renal tubular dysfunction associated with tenofovir based HAART in perinatally acquired HIV: the need for pae-diatric formulations and pharmacokinetic studies (Abstracts of the 14th Annual Conference of the British HIV Association). HIV Med 2008; 9:26.
21. Vigano A, Zuccotti GV, Martelli L, Giacomet V, Cafarelli L, Borgonovo S, et al. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig 2007; 27:573-581.
22. Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005; 116:e846-e854.
23. Riordan A, Judd A, Boyd K, Cliff D, Doerholt K, Lyall H, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatric Infect Dis J 2009; 28:204-209.
24. Gibb DM, DuongT,Tookey PA, SharlandM,Tudor-Williams G, Novelli V, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327:1019.
25. Judd A, DoerholtK,Tookey PA, SharlandM,RiordanA,Menson E, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45:918-924.
26. Atiyeh BA, Dabbagh SS, Gruskin AB. Evaluation of renal function during childhood. Pediatrics Rev 1996; 17:175-180.
27. Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda, MD: National Institutes of Health 2004.
28. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 111:1416-1421. (Pubitemid 36682280)
29. D:A:D Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
30. Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Vigano A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndrome 2005; 40:448-450.
31. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatrics 2008; 152:582-584
32. Working Groupon Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of anti-retroviral agents in paediatric infection. Bethesda: National Institutes of Health; 2008.
33. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009; 10:482-487.